Intercept raises $400M in debt offering

Hepatic disease company Intercept Pharmaceutics Inc. (NASDAQ:ICPT) raised $400 million through the sale of senior convertible notes in an offering underwritten by RBC Capital Markets, UBS, BofA Merrill Lynch, Citigroup and Credit Suisse. The notes bear 3.25% interest and mature on July 1, 2023. ...